USANA Health Sciences, Inc. — Form 10-Q Summary
Period clarification: The filing covers the quarter ended September 30, 2023, and nine months then ended, compared with the quarter ended October 1, 2022, and corresponding nine months. This differs from the request metadata identifying 2022 Q3.
Business context and reporting period
USANA develops and manufactures nutrition, personal care and skincare products, distributed primarily through independent direct-selling Associates and Preferred Customers. It reported approximately 464,000 active customers at September 30, 2023, down 2.1% year over year. Sales outside the United States were 89.6% of nine-month revenue, exposing results to foreign-exchange movements.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Net sales | $213.4m | $233.3m | $699.9m | $770.6m |
| Gross profit / margin | $170.8m / 80.1% | $186.7m / 80.0% | $565.6m / 80.8% | $623.2m / 80.9% |
| Operating earnings | $17.6m | $22.6m | $68.9m | $85.1m |
| Net earnings | $11.3m | $14.9m | $47.0m | $56.6m |
| Diluted EPS | $0.59 | $0.78 | $2.43 | $2.93 |
| Operating cash flow | Not presented quarterly | Not presented quarterly | $44.6m | $63.4m |
Quarterly sales declined 8.5%; management estimated unfavorable currency effects of $4.7 million. Nine-month sales fell 9.2% as reported and 5.6% excluding currency effects. Quarterly net earnings declined 24.0%, and nine-month diluted EPS declined 17.1%. The effective tax rate was 44.7% for Q3 versus 35.7% a year earlier and 38.0% for the nine months versus 34.1%.
At September 30, 2023, cash and cash equivalents were $307.1 million, inventories $60.1 million, current assets $390.5 million, current liabilities $112.6 million, and stockholders’ equity $470.4 million. Cash, cash equivalents and restricted cash totaled $309.8 million. There was no outstanding balance on the $75 million revolving credit facility. The facility matures in August 2025 and includes a minimum rolling four-quarter adjusted EBITDA covenant of $100 million and a maximum funded-debt-to-EBITDA ratio of 2.0:1.
Nine-month investing cash use was $4.7 million, including $7.2 million of property and equipment purchases. Financing cash use was $14.9 million, including $11.6 million of share repurchases. Cash increased by $18.5 million, including the effects of exchange rates. The company repurchased 180,000 shares during the nine months; $71.2 million remained authorized.
Material changes versus the comparable period
- Revenue declined across all reported geographic regions in Q3. Greater China revenue was down 2.8% as reported, while Southeast Asia Pacific fell 17.2% and Americas and Europe fell 14.4%.
- Management attributed sales weakness mainly to lower active-customer counts, partly offset by modest price increases. Greater China active customers increased 8.0%; Southeast Asia Pacific declined 12.6%, North Asia 9.3%, and Americas and Europe 8.9%.
- Q3 gross margin edged up 10 basis points, while associate incentives rose 10 basis points as a share of sales. SG&A declined in dollars but increased 140 basis points relative to sales, primarily because lower revenue reduced operating leverage.
- Nine-month operating cash flow fell to $44.6 million from $63.4 million, with management citing cash payments for accrued Associate incentives and the 2022 employee bonus.
- Cash and cash equivalents increased from $288.4 million at year-end 2022. Cash held in China decreased to $85.9 million from $129.8 million, while U.S. cash increased to $182.1 million from $114.1 million.
Outlook, risks and unusual items
The filing provides no quantified earnings or revenue guidance. Management said current cash, expected operating cash flow and available credit should cover ordinary-course operating and capital needs for the foreseeable future. It cautioned that adverse conditions or unusual capital needs could require financing, which may not be available on favorable terms. Transfers of profits from China to the United States may be delayed under Chinese regulatory requirements.
Key disclosed risks include reliance on direct selling and Associate activity; regulation of direct selling, particularly in China; Chinese market and data-privacy developments; macroeconomic and consumer-spending pressures; currency volatility; supply-chain and raw-material costs; cybersecurity and privacy; and compliance with credit-facility covenants. Ordinary-course lawsuits and claims are ongoing; management did not believe they would materially adversely affect financial condition, liquidity or results, but some contingencies could not be estimated. The annual goodwill and indefinite-lived-intangible impairment assessments identified no impairment.
A $548,000 contingent-consideration liability was forfeited after the relevant employee resigned, resulting in a non-cash gain reflected in the cash-flow reconciliation. The company reported no material changes to its previously disclosed risk factors or market-risk disclosures, and concluded disclosure controls were effective at September 30, 2023.
Important facts for investors to verify
- Confirm the intended reporting year: the supplied filing is for Q3 2023, not Q3 2022.
- Monitor active-customer trends and sales performance by market, especially Southeast Asia Pacific, North Asia, and the United States.
- Assess whether revenue stabilization and cash generation can offset lower sales and the higher tax rate.
- Review China cash remittance restrictions, currency exposure, and compliance with the credit-facility covenants.
- Track litigation and other contingencies, share repurchases, and the company’s use of its remaining repurchase authorization.